Stevanato Group S.p.A. (NYSE:STVN) Shares Purchased by Cooper Investors PTY Ltd.

Cooper Investors PTY Ltd. boosted its stake in Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 22.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 137,605 shares of the company's stock after purchasing an additional 25,221 shares during the quarter. Cooper Investors PTY Ltd.'s holdings in Stevanato Group were worth $2,810,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Conestoga Capital Advisors LLC raised its holdings in shares of Stevanato Group by 1.3% in the 1st quarter. Conestoga Capital Advisors LLC now owns 8,189,926 shares of the company's stock worth $167,238,000 after purchasing an additional 106,930 shares during the period. Artisan Partners Limited Partnership raised its holdings in Stevanato Group by 28.7% in the fourth quarter. Artisan Partners Limited Partnership now owns 2,355,799 shares of the company's stock valued at $51,333,000 after buying an additional 524,989 shares during the period. Bamco Inc. NY lifted its position in Stevanato Group by 7.9% during the fourth quarter. Bamco Inc. NY now owns 1,818,181 shares of the company's stock valued at $39,618,000 after buying an additional 133,000 shares in the last quarter. Teacher Retirement System of Texas grew its stake in Stevanato Group by 56.3% during the fourth quarter. Teacher Retirement System of Texas now owns 1,250,000 shares of the company's stock worth $27,238,000 after buying an additional 450,000 shares during the period. Finally, Thornburg Investment Management Inc. grew its stake in Stevanato Group by 48.1% during the fourth quarter. Thornburg Investment Management Inc. now owns 1,122,098 shares of the company's stock worth $24,451,000 after buying an additional 364,471 shares during the period.

Stevanato Group Stock Down 1.7%

STVN stock traded down €0.43 ($0.51) during mid-day trading on Friday, hitting €24.66 ($29.01). 544,543 shares of the company were exchanged, compared to its average volume of 341,100. The firm has a fifty day simple moving average of €22.97 and a 200 day simple moving average of €21.87. The company has a market capitalization of $7.47 billion, a PE ratio of 48.35, a price-to-earnings-growth ratio of 2.41 and a beta of 0.53. Stevanato Group S.p.A. has a twelve month low of €17.12 ($20.14) and a twelve month high of €25.88 ($30.45). The company has a current ratio of 1.83, a quick ratio of 1.26 and a debt-to-equity ratio of 0.22.

Stevanato Group Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, July 17th. Investors of record on Thursday, June 5th will be issued a $0.0613 dividend. This is a positive change from Stevanato Group's previous annual dividend of $0.05. This represents a yield of 0.3%. The ex-dividend date is Thursday, June 5th. Stevanato Group's payout ratio is currently 11.76%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on STVN shares. William Blair restated an "outperform" rating on shares of Stevanato Group in a research note on Friday, March 7th. Stephens upgraded shares of Stevanato Group to a "strong-buy" rating in a report on Monday, April 21st. Finally, UBS Group lowered their target price on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a research note on Friday, March 7th. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Stevanato Group presently has a consensus rating of "Moderate Buy" and a consensus price target of €25.70 ($30.24).

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.